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Abstract
Polytomous discrimination index is a novel and important diagnostic accuracy measure for multi-category classification.
After reconstructing its probabilistic definition, we propose a nonparametric approach to the estimation of polytomous
discrimination index based on an empirical sample of biomarker values. In this paper, we provide the finite-sample and
asymptotic properties of the proposed estimators and such analytic results may facilitate the statistical inference.
Simulation studies are performed to examine the performance of the nonparametric estimators. Two real data
examples are analysed to illustrate our methodology.
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1 Introduction
The outcomes of diagnostic problems in medicine sometimes involve more than two distinct categories. To
examine the classiﬁcation accuracy we must employ nonstandard accuracy measures. There are two general
approaches to extend the diagnostic measure of dichotomous discrimination, the so-called C-statistic or area
under the receiver operating characteristic curve (AUC), to polytomous problems. The ﬁrst approach evaluates
pairs of subjects from a diﬀerent category, such as the M-index,1 and Obuchowski’s pairwise C-statistic.2 The
second approach evaluates sets of subjects, where each is from a diﬀerent category. The volume under the ROC
surface (VUS), which was introduced by Mossman3 and further discussed in Dreiseitl et al.,4 is a representative
example. In short, the VUS can be interpreted as the probability that the outcome of a randomly selected set of
subjects is correctly identiﬁed. When there are more than three classes, VUS is extended to the hypervolume under
the ROC manifold (HUM).5,8,10 Besides VUS and HUM, Van Calster et al.5 introduced the polytomous
discrimination index (PDI) which is also deﬁned for a set of subjects. In this paper, we shall conduct a focused
study on this new index.
Similar to VUS, PDI is also evaluating the probability of an event related to simultaneously classifying M
subjects from M categories. In the original work,5 the authors only suggest a sample version of PDI and did not
clearly deﬁne the population parameter. In this paper, we provide an explicit deﬁnition of PDI ascribing what we
intend to achieve in the classiﬁcation task. While VUS is pertaining to the event that all M subjects are correctly
identiﬁed to their corresponding categories, PDI is pertaining to the number of subjects in the set of M subjects
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that are correctly identiﬁed to his/her category. Higher PDI values suggest better multi-class discrimination.
If some diagnostic tests or biomarkers have too low a PDI value, they should be removed from consideration
and we may reserve more attention on other qualiﬁed tests or biomarkers. Therefore, reporting PDI can also be
useful for a screening study where there are thousands of candidate biomarkers and only a few of them are truly
useful for diﬀerentiating the disease status.
In the literature there are abundant published works concerning the estimation and inference for AUC and
VUS. See Nakas and Yiannoutsos6 and Li and Fine7 for examples. However, there is only limited statistical work
on the estimation of PDI. We intend to provide a discussion on this topic in this paper. Speciﬁcally we contribute a
nonparametric estimation approach based on the probabilistic deﬁnition of PDI. Since the deﬁnition of PDI is
based on the predicted risks from diagnostic tests or models of biomarkers, we propose methods accordingly in
this paper to estimate the PDI. Besides oﬀering point estimation, we also derive the sampling variance formula to
quantify the estimation variability. Both ﬁnite sample and asymptotic properties are established to facilitate
statistical inference. Simulations and a real data example demonstrate a good performance for the proposed
estimators.
2 Definition of PDI
2.1 Conceptual definition
PDI is a useful index to quantify the multi-category discriminative ability in diagnostic medicine. Suppose there
areM categories (M  2) in a study and the research question is to predict the risk for each of theM categories. To
deﬁne the population parameter PDI, we consider a random sample that involves M subjects and each subject is
chosen from one of theM distinct categories. Without loss of generality, we assume that the ith subject is from the
ith category.
Consider randomly picking a subject from this group of M subjects and let Ai be the event that this subject is
actually from category i and Bi be the event that this subject is identiﬁed to belong to the ith category. This
classiﬁcation decision is achieved via a comparison of the M subjects. In general, a classiﬁer may use the
characteristics of the M subjects and then evaluate the probability that subject i is of class i in this group of M
subjects. We shall elaborate on this in the next section.
The PDI is given as
 ¼
XM
i¼1
PðBijAiÞPðAiÞ ð1Þ
If the individual components PðBijAiÞ are large, PDI will tend to be large. We denote the conditional probability
PðBijAiÞ by PDIi, which can be interpreted as the probability to correctly identify the class membership of the ith
subject among the M subjects. These risks can be obtained using methods to predict risks for multi-category
outcomes (see next section).
The PDI corresponds to probability of the event that a randomly selected subject from the M subjects is
correctly classiﬁed. In the literature PDI may also be interpreted as the average proportion of correctly
identiﬁed cases within a set. For example, a PDI value of 0.7 means that on average 70% of the cases in a set
are correctly identiﬁed. We note that PðAiÞ is simply 1=M for a random selection from the ﬁxed M subjects and
therefore equation (1) can be rewritten as
Conceptual Definition :  ¼ 1
M
XM
i¼1
PðBijAiÞ ð2Þ
The worst classiﬁer takes a random guess and places the ith subject into theM categories randomly. In that case
PDIi ¼ 1=M for all i and consequently the null value of PDI is 1=M as well.
We note that conceptually PDIi is quite diﬀerent from the correct classiﬁcation probability (CCP) for the ith
category, denoted by CCPi which can be interpreted as the probability of correctly identifying the ith class
membership, reducing to the familiar sensitivity and speciﬁcity under binary classiﬁcation. When evaluating
CCP, the random event only involves one randomly sampled subject from a single category. In contrast, PDIi
stipulates the probability of correctly classifying one subject in the environment of another M 1 accompanying
subjects (whose information also enters the random event).
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Deﬁnition (1) (or (2)) provides a fundamental probabilistic framework to understand PDI. However, the
random events Bi must be materialized by the variables actually used in predicting the outcome. Depending on
the classiﬁcation and prediction methods, the observation of Bi may be based on diﬀerent types of empirical data
or observed events. We consider a common setting in the next section and contribute a more practical deﬁnition of
PDI in practice.
2.2 Actionable definition
The classiﬁcation for multiple categories is most often based on the evaluated risks of the study subjects. The risks
are probability scores that are computed from individuals’ biomarker values such as microarray gene expressions,
physical and biological measurements. Speciﬁcally, we denote the probability of placing a subject from category
j into category i by pij and we have pij  0 and
PM
i¼1 pij ¼ 1 for any j.
We consider deﬁning PDI based on the distribution of pij. When there is no ordinal relationship among the
classes, ranking one particular subject correctly among the set ofM subjects can be entirely based on relative order
of predicted risk values. Speciﬁcally, the event Bi in equation (2) is equivalent to pii> pij for all j 6¼ i. This event is to
compare pij values across all of the subjects, j ¼ 1, . . .,M for a ﬁxed category i. One must distinguish this clearly
with the classiﬁcation event for the deﬁnition of CCP where we compare pij values across all the risk values,
i ¼ 1, . . .,M for a ﬁxed subject from category j.
Eﬀectively, we obtain the following equivalent deﬁnition of PDI
Actionable definition :  ¼ 1
M
XM
i¼1
Pð pii4 pij for all j 6¼ ijAiÞ ð3Þ
This deﬁnition provides a useful alternative to equation (2) since it is more actionable and may directly lead to an
empirical version for the estimation. In fact, this form of PDI can be shown to be equivalent to the original
deﬁnition.5
In practice, when the true status for a subject is unknown, we tend to assign the subject into a category
j 2 f1, . . .,Mg such that pjj is the greatest among all pij, i ¼ 1, . . .,M. Such a classiﬁcation rule is usually
adopted in the deﬁnition of CCP.8 This approach is statistically valid but rarely has clinical relevance from our
experiences. For example, cases from categories with low prevalence will mostly be misclassiﬁed, even though the
small categories are often the most important ones.
2.2.1 Null value of PDI
For M-category classiﬁcation, the null value for PDI is 1=M. This lower bound corresponds to a useless marker
which randomly assigns the subject into the M classes. In practice, any reasonable diagnostic test or biomarker
must attain a PDI value greater than the null value. One may directly evaluate the performance of the multi-
category classiﬁcation by examining how far the PDI exceeds such a nominal null value.
3 Estimation of PDI
For the simplicity of presentation, we consider a prediction problem for a polytomous outcome with M¼ 3
categories. The general multi-category formula can be easily obtained by extending the three-dimensional
estimating functions introduced below to higher dimension. Suppose we obtain the risk assessment vector
pai ¼ ð p1a,i, p2a,i, p3a,iÞT for subject i ði ¼ 1, . . ., naÞ from group a (a¼ 1, 2, 3). For category a, we may estimate
PDIa by
^a ¼ 1
n1n2n3
Xn1
i¼1
Xn2
j¼1
Xn3
k¼1
Caðp1i, p2j, p3kÞ ð4Þ
where the indicator function Ca¼ 1 if the correct identiﬁcation for the subject from category a among three
subjects each from one of the three groups is achieved and Ca¼ 0 otherwise. That is, C1ðp1i, p2j, p3kÞ ¼ 1 if
p11,i4 p12,j and p11,i4 p13,k and C1ðp1i, p2j, p3kÞ ¼ 0 otherwise; C2ðp1i, p2j, p3kÞ ¼ 1 if p22,j4 p21,i and p22,j4 p23,k
and C2ðp1i, p2j, p3kÞ ¼ 0 otherwise; C3ðp1i, p2j, p3kÞ ¼ 1 if p33,k4 p31,i and p33,k4 p32,j and C3ðp1i, p2j, p3kÞ ¼ 0
otherwise.
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For simplicity, we introduce the shorthand notation U
ðaÞ
ijk ¼ Caðp1i, p2j, p3kÞ, a ¼ 1, 2, 3. The empirical estimator
of PDI is
^ ¼ 1
3n1n2n3
Xn1
i¼1
Xn2
j¼1
Xn3
k¼1

U
ð1Þ
ijk þUð2Þijk þUð3Þijk

ð5Þ
3.1 Multinomial logistic regression
Multinomial logistic regression is a well-known classiﬁcation procedure that generalizes binary logistic regression
to multi-class problems. In another word, it may be used to predict the probabilities of the diﬀerent possible
outcomes of a categorical dependent variable, given a set of independent variables. We use this approach in our
procedure to obtain the probability assessment vector described in the preceding section.
We supply more details in this subsection. In practice, we collect an empirical sample fDi,Wigni¼1 where Di
denotes the true multi-category disease status for the ith subject andWi is the corresponding marker or test value.
A multinomial logistic regression model is given by
log
PðDi ¼ mÞ
PðDi ¼ 1Þ ¼ m0 þ m1Wi, m ¼ 2, . . .,M ð6Þ
In general, for a response with M categories, we need M 1 log-odds equations deﬁned above to formulate the
regression model. In fact the M 1 multinomial logit equations contrast each of categories 2, 3, . . .,M with the
reference category 1, whereas the binary logistic regression equation is a contrast between successes and failures.
WhenM¼ 2, this reduces to the familiar binary logistic regression model. In practice, model (6) can be ﬁtted using
the maximum likelihood methods and is now implemented in all kinds of statistical packages.
Suppose the ith subject is from class a. It is not hard to verify that model (6) may lead to the following
probability prediction for the ith subject
p1a,i ¼ 1
1þPMm¼2 expðm0 þ m1WiÞÞ ,
pma,i ¼ expðm0 þ m1WiÞ
1þPMm¼2 expðm0 þ m1WiÞÞ , 2  m M
and
PM
m¼1 pma,i ¼ 1 for any a or i. Such a vector pai ¼ ð p1a,i, p2a,i, . . ., pMa,iÞT naturally forms the probability
assessment for the ith subject where each element pma,i suggests how likely the ith subject belongs to group m.
In this paper, we ﬁrst apply multinomial logistic regression to obtain the risk prediction vectors and
subsequently compute the PDI using formula given in the preceding section. We note that this kind of two-step
evaluation approaches has been widely practiced in binary classiﬁcation problems where one constructs the ROC
curve after ﬁtting logistic regression model to the data. See for example, Chapter 8 of Vexler et al.9 One additional
beneﬁt of logistic regression is that one can incorporate covariates easily in the probability modelling.
3.2 Finite sample properties
First, it is easy to verify that Eð^Þ ¼  since EðUðaÞijk Þ ¼ PDIa for a¼ 1, 2, 3. Therefore, we obtain an unbiased
estimator for PDI.
Next we consider the exact variance of ^. After a lengthy calculation we may obtain
Varð^Þ ¼ 1
9n1n2n3
X3
a¼1
X3
b¼1
h
qðabÞ þ ðn3  1ÞqðabÞ12 þ ðn2  1ÞqðabÞ13 þ ðn1  1ÞqðabÞ23
þ ðn2  1Þðn3  1ÞqðabÞ1 þ ðn1  1Þðn3  1ÞqðabÞ2 þ ðn1  1Þðn2  1ÞqðabÞ3
i
 n1n2 þ n1n3 þ n2n3  n1  n2  n3 þ 1
n1n2n3
2 ð7Þ
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where for a, b ¼ 1, 2, 3,
qðabÞ ¼ P

U
ðaÞ
ijk ¼ UðbÞijk ¼ 1

;
q
ðabÞ
1 ¼ P

U
ðaÞ
ijk ¼ UðbÞiJK ¼ 1

, J 6¼ j,K 6¼ k;
q
ðabÞ
2 ¼ P

U
ðaÞ
ijk ¼ UðbÞIjK ¼ 1

, I 6¼ i,K 6¼ k;
q
ðabÞ
3 ¼ P

U
ðaÞ
ijk ¼ UðbÞIJk ¼ 1

, I 6¼ i, J 6¼ j;
q
ðabÞ
12 ¼ P

U
ðaÞ
ijk ¼ UðbÞijK ¼ 1

, K 6¼ k;
q
ðabÞ
13 ¼ P

U
ðaÞ
ijk ¼ UðbÞiJk ¼ 1

, J 6¼ j;
q
ðabÞ
23 ¼ P

U
ðaÞ
ijk ¼ UðbÞIjk ¼ 1

, I 6¼ i
The technical derivation of equation (7) is contained in Appendix 1.
It is worth noting that all of the above quantities are exchangeable between a and b with the same subscripts.
That is
qðabÞ ¼ qðbaÞ, qðabÞa0 ¼ qðbaÞa0 , qðabÞa0b0 ¼ qðbaÞa0b0
where a0, b0 ¼ 1, 2, 3. Speciﬁcally, if a¼ b
qðaaÞ ¼ P

U
ðaÞ
ijk ¼ 1

¼ PDIa, a ¼ 1, 2, 3
Moreover, since these probability terms are unknown in practice, their estimators can be obtained by
calculating the empirical fractions. For example, q
ðabÞ
12 can be estimated by
q^
ðabÞ
12 ¼
1
n1n2n3ðn3  1Þ
Xn1
i¼1
Xn2
j¼1
Xn3
k¼1
X
K 6¼k
U
ðaÞ
ijkU
ðbÞ
ijK
3.3 Asymptotic properties
We also note that the estimator ^i is consistent to PDIi by the strong law of large numbers for each i, and therefore,
the estimator of ^ converges to the true value of PDI  as the sample size tends to inﬁnity.
Furthermore, let n ¼ n1 þ n2 þ n3. Suppose
lim
n!1
n
n1
¼ 1, lim
n!1
n
n2
¼ 2, lim
n!1
n
n3
¼ 3 ð8Þ
where 1, 2, 351 are some positive real numbers. Then as n!1, we can show
Varð ﬃﬃﬃnp ^Þ ! 1
9
X3
a¼1
X3
b¼1

1q
ðabÞ
1 þ 2qðabÞ2 þ 3qðabÞ3

 ð1 þ 2 þ 3Þ2 :¼ 21
Using the central limit theorem for U-statistics, we can show thatﬃﬃﬃ
n
p ð^  Þ !d Nð0, 21Þ ð9Þ
The asymptotic distribution may facilitate the statistical inference for PDI. We may construct the ð1 Þ100%
asymptotic conﬁdence interval for  by ^  z=21 where z is the upper  percentile of the standard normal
distribution. The terms included in the variance parameter may be estimated by empirical estimates easily in
practice.
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3.4 Covariates adjustment
It is often important to assess the importance of the biomarkers in the presence of risk factors or confounders such
as age, sex and body mass index (bmi). When constructing PDI and its estimators, we may consider some proper
adjustment to take covariates eﬀects into account.
We note that the proposed PDI for marker j is based on the random distribution of fpijg. In order to adjust
other covariates, we may obtain pij through a multivariate regression model incorporating the available covariates.
In practice, for a multi-category classiﬁcation problem, the calibrated pij values are usually based on a ﬁtted
multinomial logistic regression model. It is straightforward to include risk factors or confounders in the model
and facilitate the computation of covariate-adjusted PDI.
There are also other possible approaches to adjust covariates. For example, one may stratify the sample space
according to diﬀerent covariate characteristics and then compute PDI values for diﬀerent strata. This method may
be useful when we only adjust for a small number of covariates. When the cluster numbers increase, the
information in each covariate cluster may be limited and the calculation of such covariate-adjusted PDI may
be less precise. Another adjustment method may be based on a multi-class regression system between the marker
values and the covariates. One may then construct covariate-speciﬁc marker distributions for multiple classes.
Such a method was adopted for three-way ROC analysis in Li et al.10 The complete development of such a
regression approach is beyond the scope of this paper.
4 Simulation
In order to assess the ﬁnite sample performance of our estimation procedures, we performed numerical studies
using 500 simulations. At each simulation, diagnostic test results for three categories were independently generated
from three diﬀerent populations, and the sample sizes were designed such that outcome prevalences are balanced
(n1 ¼ n2 ¼ n3 ¼ 50, 100, or 200) or imbalanced (n1 ¼ 50, n2 ¼ 100, n3 ¼ 150).
We denote the marker values from the three classes by X, Y and Z, respectively, and consider four diﬀerent
distribution scenarios in the following:
Case I. The normal populations: X  Nð0, 1Þ,Y  Nð1, 1Þ and Z  Nð2, 1Þ.
Case II. The normal populations: X  Nð0, 1Þ,Y  Nð1:5, 1Þ and Z  Nð3, 1Þ.
Case III. The exponential populations: X  Expð3Þ,Y  Expð2Þ and Z  Expð1Þ.
Case IV. The exponential populations: X  Expð2Þ,Y  Expð1=2Þ and Z  Expð1=4Þ.
Case V. The exponential populations: X,Y,Z  Expð1Þ. In this case, the marker is a random guess and the PDI
corresponds to a null value.
Using a very large number Monte Carlo sample (n¼ 10, 000), we can obtain the true value of PDI in the four
cases. For each simulated data, we used the nonparametric estimator (5) to estimate the PDI. Speciﬁcally, we ﬁtted
a multinomial logistic regression model to generate the sample of predicted risks and then applied our estimator.
The simulation results in all scenarios with equal and unequal sample sizes were summarized in Tables 1 and 2.
The estimated PDIs are all very close to the true values. The estimated standard errors are also quite similar to the
standard deviations of the estimates. Coverage rates of the 95% asymptotical conﬁdence intervals for PDI were
also reported. The coverage is quite close to the nominal conﬁdence level. From such numerical results, we can see
that the proposed method performs very well.
5 Examples
5.1 Liver cancer
We examined a liver cancer mass spectrometry dataset14,15 as an example to illustrate our methods. In this dataset,
there are 202 participants from Cairo, Egypt: 73 hepatocellular carcinoma (denoted by HC) cases, 77 healthy
individuals (denoted by NC) and 52 patients with chronic liver disease (denoted by QC). The spectra were
generated by matrix-assisted laser desorption/ionization time-of-ﬂight mass analyser (Applied Biosystems Inc.,
Framingham, MA, USA). We downloaded the dataset from the authors’ public website.
We preprocessed the raw spectra using standard routines of simultaneous peak detection and baseline
correction (SPDBC). We used a package Cromwell11 developed in house at M.D. Anderson to perform the
SPDBC on each spectrum. The mass-to-charge ratio (M/Z) of the protein from the observed ﬂight time is
computed based on a quadratic transformation of signals produced from the mass spectrometry instruments.11
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The SPDBC algorithm produced a list of M/Z values corresponding to peaks and also a baseline-corrected
spectrum. We then normalized each modiﬁed spectrum to the total ion current for the region of M=Z ¼ 2000th
and above. Intensities atM/Z values below this showed frequent saturation. We focus on a total of 484 peaks that
resulted from preprocessing of the raw data.
We note that in the biostatistical literature the terms ‘peaks’, ‘biomarkers’, ‘tests’ and ‘intensities’ are used
interchangeably for certain biomedical studies. In fact ‘peaks’ and ‘intensities’ have broader biological meanings.
In this paper, we only focus on their numerical attributes and use the magnitude of peaks or intensities to predict
the disease status. They thus play the same role as a traditional diagnostic test.
For each peak we computed the estimated PDI using formula (5). We then listed the top 20 peaks ranked by
PDI values in Table 3. From the ranking list, we notice that peak 183 is the best peak with PDI value over 70%,
indicating the chance that at least one disease category can be correctly identiﬁed in a three-category classiﬁcation
set-up. This peak has been previously reported to be important with the highest HUM. Our ﬁndings in this paper
echo previous observations and add further evidence to support the study of such important spectrometry
markers.
We have conducted bootstrap tests to compare the PDI values between the markers. The diﬀerence of
PDI values between the top two peaks is not signiﬁcant with p-value 0.582. This indicates that the top two
peaks may perform with very similar accuracy in a classiﬁcation task. In fact, the bootstrap tests suggest the
diﬀerences of PDI between the top four peaks are not signiﬁcant. The diﬀerence between the ﬁrst and the ﬁfth
peaks becomes signiﬁcant (bootstrap p-value 0.049). When performing multiple hypothesis tests, we might inﬂate
the familywise type I error rate. In practice, we can adjust the p-values using Bonferroni correction or other similar
methods.
Table 1. Simulation results for estimating PDI with same sample sizes.
Case True Sample size dPDI Bias SD MSE SE Coverage
I 0.6425 50 .6400 0.0025 0.0377 0.0037 0.0365 0.958
100 .6415 0.0010 0.0256 0.0021 0.0263 0.956
200 .6411 0.0014 0.0194 0.0008 0.0142 0.948
II 0.7711 50 .7782 0.0071 0.0331 0.0035 0.0324 0.964
100 .7803 0.0098 0.0243 0.0018 0.0232 0.955
200 .7686 0.0025 0.0140 0.0006 0.0169 0.958
III 0.4834 50 .4889 0.0055 0.0384 0.0030 0.0262 0.954
100 .4844 0.0010 0.0262 0.0015 0.0262 0.946
200 .4835 0.0001 0.0188 0.0007 0.0110 0.946
IV 0.6165 50 .6179 0.0014 0.0342 0.0024 0.0333 0.940
100 .6155 0.0010 0.0240 0.0013 0.0239 0.962
200 .6156 0.0009 0.0166 0.0006 0.0094 0.952
V 0.3333 50 .3698 0.0345 0.0268 0.0026 0.0369 0.946
100 .3574 0.0221 0.0187 0.0012 0.0268 0.954
200 .3501 0.0148 0.0125 0.0007 0.0178 0.952
PDI: Polytomous discrimination index.dPDI and SD are the mean and standard deviation of the estimated PDI values over 500 simulations; bias is the average of the differences between dPDI
and the true value of PDI; MSE is the average of the squared errors of dPDI; SE is the mean of the estimated standard errors of dPDI computed based on
equation (7); coverage is the coverage proportion of the 95% confidence interval constructed by ½dPDI 1:96SE,dPDIþ 1:96SE.
Table 2. Simulation results for estimating PDI with sample sizes n1 ¼ 50, n2 ¼ 100 and n3 ¼ 150.
Case True dPDI Bias SD MSE SE Coverage
I 0.6425 .6276 0.0148 0.0251 0.0019 0.0292 0.956
II 0.7711 .7552 0.0159 0.0219 0.0019 0.0285 0.948
III 0.4834 .4768 0.0065 0.0245 0.0012 0.0236 0.960
IV 0.6165 .6102 0.0063 0.0284 0.0016 0.0280 0.954
V 0.3353 .3590 0.0237 0.0204 0.0013 0.0226 0.948
PDI: Polytomous discrimination index.
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The PDI analysis for these data may serve as a necessary initial screening step for biomarker studies. The peaks
with high PDI values may be further analysed in the subsequent modelling and analysis. We note that knowing
how often the marker identiﬁes one category does not guarantee the marker can be directly applied in clinical
prediction. Further experiments and analyses may be necessary to enhance our understanding of the marker.
5.2 Immunohistochemical synovial biomarkers
Although the methodology we introduced has been contextualized to three-category classiﬁcation problems, there
is little diﬃculty in extending our results to higher dimensional classiﬁcations. In this section, we analyse a medical
data with six distinct categories.
Immunohistochemical synovial tissue biomarkers are used increasingly to classify arthropathies, study their
pathogenesis and to measure disease activity in clinical trials. Synovial tissue specimens were obtained by closed
needle biopsy or surgically at the time of arthroplasty.12 The following specimen samples were included:
(1) noninﬂamed control specimens (n¼ 22), consisting of biopsies from healthy volunteers and patients with
noninﬂammatory knee pain, which were indistinguishable from the normal specimens by a variety of
histological and immunohistochemical markers; (2) rheumatoid arthritis with active disease despite disease-
modifying antirheumatic drug (DMARD) treatment (n¼ 28); (3) early undiﬀerentiated arthritis (duration <12
months, n¼ 10); (4) chronic (disease duration >4 weeks) septic arthritis proven by positive bacterial culture
(n¼ 11); (5) noninﬂammatory orthopaedic arthropathies (Orth.A, n¼ 23, consisting of femur fracture, n¼ 3;
avascular necrosis of the femur, n¼ 3; meniscus and/or ligament injury, n¼ 13, and plica syndrome, n¼ 4); (6)
osteoarthritis (OA, n¼ 31). General antigen preservation was tested by staining for von Willebrand Factor.
The six types of disease status indicate diﬀerent medical conditions and require entirely diﬀerent treatment
programmes for the patients. Accurate discrimination for an individual’s disease category is thus important for the
subsequent decision making. Researchers investigated ﬁve synovial biomarkers and studied their discrimination
ability.12 Speciﬁcally, tissues were ﬁxed in formalin and embedded in paraﬃn according to standard practice. Five
micrometre thick sections were immunostained on a semi-automated staining system (Ventana Benchmark,
Ventana, Tucson, AZ) for CD3 (T cells, antibody clone PS1), CD20 (B cells, L-26), CD15 (neutrophilic
granulocytes, MMA), CD38 (plasma cells, SPC32), CD68 (macrophages, Kp1). We used methods proposed in
this paper and computated the PDI for these markers. The estimation results are reported in Table 4.
Table 3. Top 20 peaks ranked by PDI.
Rank Peak ID dPDI SE
1 183 0.7289 0.0295
2 147 0.7174 0.0299
3 209 0.7122 0.0306
4 443 0.6814 0.0287
5 182 0.6623 0.0318
6 262 0.6549 0.0316
7 239 0.6470 0.0324
8 368 0.6424 0.0305
9 299 0.6419 0.0323
10 472 0.6413 0.0288
11 188 0.6361 0.0247
12 134 0.6298 0.0321
13 425 0.6237 0.0332
14 306 0.6228 0.0312
15 361 0.6219 0.0309
16 104 0.6216 0.0322
17 294 0.6146 0.0339
18 311 0.6120 0.0323
19 483 0.6084 0.0316
20 248 0.6083 0.0321
PDI: Polytomous discrimination index.dPDIs are estimated parameters computed by equation (5); SEs are the estimated standard errors computed based
on equation (7).
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The estimated PDI values for CD15, CD3, CD38 and CD68 are all above 440%. Recall that the null PDI
value is 1=6 ¼ 0:1667 in this case and a PDI equal to 0.42 is 2.5 times of the lower bound. CD20 was a relatively
weak marker according to its PDI, indicating that the probability of correctly identifying one of the six classes is
lower than 30%. The PDI values are not signiﬁcantly diﬀerent between CD15, CD3, CD38 and CD68 (bootstrap
p-value> .05) while the PDI of CD20 is signiﬁcantly lower than the other four biomarkers (bootstrap
p-value< .05). We may thus focus more on the four strong markers in the future follow-up investigation. We
note that the PDI for CD15 is the highest for discriminating the six categories. Such results agree with earlier
ﬁndings in the medical literature.4,13,15–19
The analysis based on PDI directly provided an order on the strength of synovial biomarkers in this example. In
comparison, Ogdie et al.12 studied sensitivity, speciﬁcity and Youden index for pairwise two category analysis.
Such measures may not be the most appropriate for a multi-category classiﬁcation accuracy study and PDI can
contribute and complement important information on the marker discrimination ability. Further clinical studies
may adopt our methodology to improve the practice for similar data analysis.
6 Discussion
The distribution results for PDI estimator in this paper provide a foundation for statistical inference. In particular,
the quantiﬁcation of estimation variability enables the construction of interval estimation for PDI and facilitates
understanding and assessment of their population location.
In practice, it is useful to start with PDI as an overall indication of discrimination. In a second step, pairwise
C-statistics can be calculated to ﬁnd out which categories can be well discriminated. Van Calster et al.13 looked
into this previously and concluded that the conditional risk method is best used to obtain pairwise C-statistics.
The estimated PDI results can be applied to evaluate the discrimination accuracy of individual biomarkers as
well as structured risk prediction models. To assess calibration of model-based risks for multi-category
classiﬁcation, i.e. whether the risks predictions are correct, Van Hoorde et al.14 proposed a ﬂexible spline-based
tool. Implementing such nonparametric regression analysis to investigate calibration of risk predictions may be
interesting and necessary for many health studies. More theoretical studies may be conducted to aﬃrm the
advantage of such a functional model.
The frequentist maximum likelihood estimation approach is usually carried out for multinomial logistic
regression modelling. This is what we adopt in this paper. In contrast, one may use Bayesian method to
develop similar estimates for regression parameters and PDI. A crucial step for Bayesian estimation is the
speciﬁcation of prior distribution. Experiences and preliminary data information can be utilized to construct a
reasonable prior. We leave such a development for future research.
The strength of a diagnostic test or biomarker may be assessed by PDI and various other discriminative
accuracy measures. Facing a multi-category classiﬁcation problem, we wish to point out that many other useful
statistics should also be considered. For example, ordinal C-statistics were proposed6,16,18,20 and may be especially
helpful when there is available information for the class order. Examining PDI, HUM and the ordinal C-statistic
may provide helpful information from diﬀerent perspectives to practitioners about the classiﬁcation capacity of the
diagnostic test.
We note that the magnitude of PDI should be interpreted with respect to the total number of categories. For an
M class problem, we can compare the estimated PDI of the marker with the null value 1=M. A well-performed
marker should have a PDI much greater than the null value. In general, the absolute PDI value for a single marker
tends to be small for very large number of classes. Usually multiple markers can be combined to build a stronger
classiﬁer with improved PDI. Further research is needed to aid in the interpretation of obtained PDI values.
Table 4. PDI for synovial biomarkers.
Biomarkers dPDI Variance 95% Confidence interval
CD15 0.4567 0.0026 ð0:3563, 0:5571Þ
CD3 0.4243 0.0028 ð0:3198, 0:5288Þ
CD20 0.2731 0.0016 ð0:1957, 0:3505Þ
CD38 0.4245 0.0048 ð0:2895, 0:5595Þ
CD68 0.4424 0.0028 ð0:3387, 0:5461Þ
PDI: Polytomous discrimination index.
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Appendix 1
Proof of equation (7). Denote a ¼ PDIa and ^a is the corresponding empirical estimate. For any a, b ¼ 1, 2, 3, the
covariance of ^a and ^b can be written as
Covð^a, ^bÞ ¼ 1
n21n
2
2n
2
3
	
Xn1
i¼1
Xn2
j¼1
Xn3
k¼1
Xn1
I¼1
Xn2
J¼1
Xn3
K¼1
Cov

U
ðaÞ
ijk ,U
ðbÞ
IJK

ð10Þ
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Note that for any i, j and k ð1  i  n1, 1  j  n2, 1  k  n3Þ,
E

U
ðaÞ
ijk

¼ PðCaðp1,i, p2,j, p3,kÞ ¼ 1Þ ¼ a, a ¼ 1, 2, 3
We thus have that for all a, b ¼ 1, 2, 3,
Cov

U
ðaÞ
ijk ,U
ðbÞ
IJK

¼ E

U
ðaÞ
ijkU
ðbÞ
IJK

 ab ð11Þ
The independence of fXi,Yj,Zkg implies that the covariance of UðaÞijk and UðbÞIJK is 0 if i 6¼ I, j 6¼ J and k 6¼ K. Then
it follows by equation (11) that the sixfold sum in equation (10) can be split into 23  1 ¼ 7 parts. That is
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The seven terms in the right-hand side of the above formula can be computed in a similar way. It is not hard to
see that the ﬁrst term is equal to n1n2n3að1 aÞ, since
E

U
ðaÞ
ijkU
ðbÞ
ijk

 ab ¼ qðabÞ  ab
is counted n1n2n3 times. Therefore, for any a, b ¼ 1, 2, 3
Covð^a, ^bÞ ¼ 1
n1n2n3

ðqðabÞ  abÞ þ ðn3  1ÞðqðabÞ12  abÞ þ ðn2  1ÞðqðabÞ13  abÞ
þ ðn1  1ÞðqðabÞ23  abÞ þ ðn2  1Þðn3  1ÞðqðabÞ1  abÞ
þ ðn1  1Þðn3  1ÞðqðabÞ2  abÞ þ ðn1  1Þðn2  1ÞðqðabÞ3  abÞ
 ð12Þ
From the relation ^ ¼ ð^1 þ ^2 þ ^3Þ=3, we have
Varð^Þ ¼ 1
9
X3
a¼1
X3
b¼1
Covð^a, ^bÞ
which, together with equation (12), implies that
Varð^Þ ¼ 1
9n1n2n3
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þ ðn1  1ÞðqðabÞ23  abÞ þ ðn2  1Þðn3  1ÞðqðabÞ1  abÞ
þ ðn1  1Þðn3  1ÞðqðabÞ2  abÞ þ ðn1  1Þðn2  1ÞðqðabÞ3  abÞÞ
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h
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þ ðn2  1Þðn3  1ÞqðabÞ1 þ ðn1  1Þðn3  1ÞqðabÞ2 þ ðn1  1Þðn2  1ÞqðabÞ3
 ðn1n2 þ n1n3 þ n2n3  n1  n2  n3 þ 1Þab
i
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¼ 1
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i
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ðn1n2 þ n1n3 þ n2n3  n1  n2  n3 þ 1Þð1 þ 2 þ 3Þ2
Then equation (7) holds.
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